JPWO2020118202A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020118202A5
JPWO2020118202A5 JP2021531817A JP2021531817A JPWO2020118202A5 JP WO2020118202 A5 JPWO2020118202 A5 JP WO2020118202A5 JP 2021531817 A JP2021531817 A JP 2021531817A JP 2021531817 A JP2021531817 A JP 2021531817A JP WO2020118202 A5 JPWO2020118202 A5 JP WO2020118202A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
elasestrant
estrogen receptor
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531817A
Other languages
English (en)
Japanese (ja)
Other versions
JP7497353B2 (ja
JP2022511497A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064980 external-priority patent/WO2020118202A1/en
Publication of JP2022511497A publication Critical patent/JP2022511497A/ja
Publication of JPWO2020118202A5 publication Critical patent/JPWO2020118202A5/ja
Application granted granted Critical
Publication of JP7497353B2 publication Critical patent/JP7497353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531817A 2018-12-06 2019-12-06 Esr1変異を含むモデルにおいて癌を治療するための方法 Active JP7497353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
US62/776,338 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (3)

Publication Number Publication Date
JP2022511497A JP2022511497A (ja) 2022-01-31
JPWO2020118202A5 true JPWO2020118202A5 (ru) 2022-12-19
JP7497353B2 JP7497353B2 (ja) 2024-06-10

Family

ID=

Similar Documents

Publication Publication Date Title
JP2018518529A5 (ru)
JP2018514549A5 (ru)
RU2017140675A (ru) Способы лечения рака
EP4157465A2 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
Shah et al. Hormone receptor–positive/human epidermal growth receptor 2–negative metastatic breast cancer in young women: emerging data in the era of molecularly targeted agents
WO2016091165A1 (zh) 治疗非小细胞肺癌的喹啉衍生物
EP4218820A2 (en) Combination therapies for the treatment of breast cancer
CA3121930A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
JPWO2020118213A5 (ru)
US20230129787A1 (en) Methods for treating ovarian cancer
JPWO2020118202A5 (ru)
RU2021116293A (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
RU2021116084A (ru) Способы лечения рака на моделях, имеющих мутации esr1
Guan et al. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis
WO2013119607A2 (en) Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
Cosentini et al. Case report: exceptional response to second line temozolomide therapy in a patient with metastatic adrenocortical carcinoma
Heidenreich et al. Targeted therapy in patients with metastatic male germ cell tumors
Tamborero Noguera et al. Cancer bioMarkers database
WO2020242795A1 (en) A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor
RU2772432C2 (ru) Способы лечения рака яичника
Mathew et al. Clinical Evidence of Regorifenib in Metastatic Colorectal Cancer: A Case Report
US20240096469A1 (en) Methods of predicting responses to disease treatments
우고운 Clinical Implication of Next Generation Sequencing for Patients with Metastatic Breast Cancer
WO2016091167A1 (zh) 抗肺鳞癌的喹啉衍生物
WO2019174590A1 (zh) 用于治疗三阴性乳腺癌的喹啉衍生物